Close

Biotechnology News Distributed by Business Wire

BIO offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave BIO’s website and will be redirected to another site. These sites are not under the control of BIO. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. Also, please be aware that the security and privacy policies on these sites may be different than BIO policies, so please read third party privacy and security policies closely.



<br /> Top 10 Bioprocess Technology Market 2017-2021: Market is Expected to Reach USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016 - Research and Markets<br />

Thu, 16 Feb 2017 14:39:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021" report to their offering. The top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between
http://www.businesswire.com/news/home/20170216005751/en/Top-10-Bioproces...
20170216005751en


<br /> Samenvatting: Asterand Biosience en MolecularMD werken samen voor versnelde validatie van therapeutische biomarkers, optimalisatie, ontwikkeling en vermarkting<br />Thu, 16 Feb 2017 14:18:00 UT

PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT--(BUSINESS WIRE)--Asterand Bioscience, leider in kwalitatief hoogwaardig en goed gekarakteriseerd menselijk weefsel en daarop gebaseerde systemen ter ondersteuning van medicijnonderzoek, heeft vandaag zijn samenwerking met MolecularMD aangekondigd. Hiermee combineren ze de expertise van MolecularMD in moleculaire diagnostiek met Asterand Bio’s capaciteiten op vlak van medicijntargeting en validatie van kandidaat-medicijnen. MolecularMD is een bedrijf
http://www.businesswire.com/news/home/20170216005717/nl/?feedref=JjAwJuN...
20170216005717nl


<br /> Helius Medical Technologies, Inc. Closes C$12.5 Million Public Offering of Class A Common Stock, Including Full Exercise of Over-Allotment Option<br />Thu, 16 Feb 2017 14:09:00 UT

NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. Closes C$12.5 Million Public Offering of Class A Common Stock, Including Full Exercise of Over-Allotment Option
http://www.businesswire.com/news/home/20170216005706/en/Helius-Medical-T...
20170216005706en


<br /> 908 Devices Optimizes High-Quality Mass Spec Analysis Through Partnership Agreement with Thermo Fisher Scientific<br />Thu, 16 Feb 2017 14:02:00 UT

BOSTON--(BUSINESS WIRE)--908 Devices, a pioneer of ridiculously small and elegantly simple analytical devices for chemical and biomolecule analysis, today announced the signing of a Value Added Reseller (VAR) Agreement with Thermo Fisher Scientific, the world leader in serving science. This co-exclusive two-year partnership agreement empowers Thermo Fisher to sell ZipChipTM as a complementary front-end separations platform with its High Resolution Accurate Mass (HRAM) mass spectrometry (MS) ins
http://www.businesswire.com/news/home/20170216005179/en/908-Devices-Opti...
20170216005179en


<br /> Innomar Strategies Enhances Market Access Expertise with Acquisition of Wyatt Health Management<br />Thu, 16 Feb 2017 14:00:00 UT
OAKVILLE, Ontario--(BUSINESS WIRE)--Innomar Strategies, Canada’s leading specialty pharmaceuticals service provider and a part of AmerisourceBergen, announced today the acquisition of Wyatt Health Management.
http://www.businesswire.com/news/home/20170216005036/en/Innomar-Strategi...
20170216005036en


<br /> RTI Surgical® Schedules 2016 Fourth Quarter, Year End Earnings and Conference Call for Feb. 23, 2017<br />Thu, 16 Feb 2017 14:00:00 UT

ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical® Schedules 2016 Fourth Quarter, Year End Earnings and Conference Call for Feb. 23, 2017
http://www.businesswire.com/news/home/20170216005493/en/RTI-Surgical%C2%...
20170216005493en


<br /> Global Regenerative Medicine Partnering 2010-2017: Deal Trends, Players, Financials and Forecasts - Research and Markets<br />Thu, 16 Feb 2017 13:58:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts" report to their offering. The Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering dea
http://www.businesswire.com/news/home/20170216005697/en/Global-Regenerat...
20170216005697en


<br /> Resumen: Zoetis obtiene la aprobación de la Comisión Europea para Stronghold® Plus<br />Thu, 16 Feb 2017 13:21:00 UT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) ha anunciado que la Comisión Europea ha concedido a la empresa la licencia para Stronghold® Plus (selamectina/sarolaner), una combinación tópica de pasasiticidas para el tratamiento de garrapatas, pulgas, ácaros de oídos, piojos y nematodos gastrointestinales y previene la dirofilariasis en gatos. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser c
http://www.businesswire.com/news/home/20170216005667/es/?feedref=JjAwJuN...
20170216005667es


<br /> QuintilesIMS Named to FORTUNE’s 2017 List of “World’s Most Admired Companies”<br />Thu, 16 Feb 2017 13:05:00 UT

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--QuintilesIMS Named to FORTUNE’s 2017 List of “World’s Most Admired Companies”
http://www.businesswire.com/news/home/20170216005659/en/QuintilesIMS-Nam...
20170216005659en


<br /> Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)<br />Thu, 16 Feb 2017 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint. There were three comparis
http://www.businesswire.com/news/home/20170216005397/en/Pfizer-Announces...
20170216005397en


<br /> Charles River Associates (CRA) Declares Quarterly Dividend<br />Thu, 16 Feb 2017 13:00:00 UT

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that its Board of Directors has declared a quarterly cash dividend of $0.14 per share to be paid on March 17, 2017 to all holders of record of CRA’s common stock as of the close of business on February 27, 2017. The Company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain subj
http://www.businesswire.com/news/home/20170216005584/en/Charles-River-As...
20170216005584en


<br /> Resumen: Asterand Bioscience y MolecularMD anuncian alianza para acelerar la validación, optimización, desarrollo y comercialización de biomarcadores terapéuticos objetivados<br />Thu, 16 Feb 2017 12:48:00 UT

PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT--(BUSINESS WIRE)--Asterand Bioscience, proveedor líder de tejidos humanos bien caracterizados y de alta calidad, así como soluciones de investigación basada en tejidos humanos que ayudan al descubrimiento y desarrollo de fármacos, ha anunciado una alianza con MolecularMD para combinar la experiencia de ésta como proveedor de productos y servicios de diagnóstico molecular con las capacidades de validación de candidatos y objetivo de fármacos de Asteran
http://www.businesswire.com/news/home/20170216005640/es/?feedref=JjAwJuN...
20170216005640es


<br /> Xcell Biosciences Announces $12 Million Series A Funding Round<br />Thu, 16 Feb 2017 12:30:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences announced today the company has closed a $12 million Series A private equity financing round led by HBM Genomics.
http://www.businesswire.com/news/home/20170216005251/en/Xcell-Bioscience...
20170216005251en


<br /> Catalent Completes Accucaps Acquisition to Expand Softgel Development and Manufacturing Capabilities and Capacity<br />Thu, 16 Feb 2017 12:30:00 UT

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (Catalent) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the acquisition of Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed. The
http://www.businesswire.com/news/home/20170216005248/en/Catalent-Complet...
20170216005248en


<br /> Zoetis erhält Zulassung der Europäischen Kommission für Stronghold® Plus<br />Thu, 16 Feb 2017 12:15:00 UT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) gab heute bekannt, dass die Europäische Kommission dem Unternehmen eine Lizenz für Stronghold® Plus (Selamectin/Sarolaner) gewährt hat, ein Kombinations-Kontakt-Parasitizid zur Behandlung gegen Zecken, Flöhe, Ohrmilben, Läuse und Fadenwürmer und zur Vorbeugung der Herzwurmkrankheit bei Katzen. Tierärztinnen und -ärzte in der gesamten Europäischen Union verfügen nun über eine Behandlungsmethode mit den Vorteilen von Sarolaner, einer Innov
http://www.businesswire.com/news/home/20170216005615/de/?feedref=JjAwJuN...
20170216005615de


<br /> Symbiotix Biotherapies Announces Issuance of First Composition of Matter Patent Covering a Microbiome-derived Therapeutic Molecule<br />Thu, 16 Feb 2017 12:00:00 UT

BOSTON--(BUSINESS WIRE)--#Biotherapies--Symbiotix Biotherapies Announces Issuance of First Composition of Matter Patent Covering a Microbiome-derived Therapeutic Molecule
http://www.businesswire.com/news/home/20170216005090/en/Symbiotix-Biothe...
20170216005090en


<br /> Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd<br />Thu, 16 Feb 2017 12:00:00 UT

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd
http://www.businesswire.com/news/home/20170216005104/en/Spectrum-Pharmac...
20170216005104en


<br /> Glaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA®<br />Thu, 16 Feb 2017 12:00:00 UT

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in the pivotal phase of its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial for the iStent SUPRA® Suprachoroidal Micro-Bypass Stent. The iStent SUPRA prospec
http://www.businesswire.com/news/home/20170216005253/en/Glaukos-Complete...
20170216005253en


<br /> Zoetis Reports Fourth Quarter and Full Year 2016 Results<br />Thu, 16 Feb 2017 12:00:00 UT

PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis reports fourth quarter and full year 2016 results.
http://www.businesswire.com/news/home/20170216005582/en/Zoetis-Reports-F...
20170216005582en


<br /> World Paediatric Vaccine Market (2014-2022) - Opportunities & Forecasts - Growth Attributed to Improved Understanding of Immunology - Research and Markets<br />Thu, 16 Feb 2017 11:32:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "World Paediatric Vaccine Market - Opportunities and Forecasts, 2014 - 2022" report to their offering. Vaccine provides protection against particular diseases by improving immunity. Vaccines are the biological preparations of weakened or killed microorganism, its surface proteins or its toxins. The global paediatric vaccine market is expected to witness a strong growth during the forecast period due to launch of new
http://www.businesswire.com/news/home/20170216005568/en/World-Paediatric...
20170216005568en


<br /> Knopp Biosciences Announces NIH Blueprint Grant Award for Advancing Novel Neonatal Epilepsy Treatments<br />Thu, 16 Feb 2017 11:00:00 UT

PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced that the National Institutes of Health Blueprint Neurotherapeutics Network has awarded the company a grant under the Small Business Innovation Research (SBIR) program to advance novel treatments for epilepsy. Terms of the grant provide the potential for up to $2.5 million of direct support based on milestone attainment. The award supports Knopp’s preclinical and clinical development of small-molecule drug candidates directed to
http://www.businesswire.com/news/home/20170216005078/en/Knopp-Bioscience...
20170216005078en


<br /> ICON Reports Fourth Quarter and Full Year 2016 Results<br />Thu, 16 Feb 2017 11:00:00 UT

DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2016 Results
http://www.businesswire.com/news/home/20170216005507/en/ICON-Reports-Fou...
20170216005507en


<br /> Clintec Marks 20th Year of Global Clinical Research with Launch of New Brand<br />Thu, 16 Feb 2017 10:46:00 UT
GLASGOW, Scotland--(BUSINESS WIRE)--Clintec today announces the launch of its new brand identity - reflected in their newly created website. This in part marks Clintec’s 20th anniversary and the achievement of significant milestones following another year of substantial growth, together with a succession of key appointments that have enhanced the global leadership team. Clintec, a multi-award winning and privately woman-owned full-service Clinical Research Organisation (CRO) which embraces dive
http://www.businesswire.com/news/home/20170216005522/en/Clintec-Marks-20...
20170216005522en


<br /> MOLOGEN AG: New positive data on lefitolimod in HIV<br />Thu, 16 Feb 2017 10:38:00 UT

BERLIN--(BUSINESS WIRE)--The biotech company MOLOGEN AG announced today that its partner, the Danish Aarhus University Hospital, presented new data on the TEACH study at the annual CROI in Seattle, USA.
http://www.businesswire.com/news/home/20170216005517/en/MOLOGEN-AG-posit...
20170216005517en


<br /> Zymeworks Receives Second Orphan Drug Designation for ZW25 in Gastric Cancer<br />Thu, 16 Feb 2017 10:00:00 UT

VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that its lead product candidate, ZW25, has been granted orphan drug designation from the U.S. Food and Drug Administration (the “FDA”) in the treatment of gastric cancer, including cancer of the gastroesophageal ju
http://www.businesswire.com/news/home/20170216005302/en/Zymeworks-Receiv...
20170216005302en


MyHeritage Presenta Photo Discoveries™Thu, 16 Feb 2017 10:00:00 UT

TEL AVIV, Israel & LEHI, Utah--(BUSINESS WIRE)--MyHeritage, el principal destino internacional de historia familiar y ADN, anunció hoy el lanzamiento de Photo Discoveries, una característica innovadora que transforma los árboles genealógicos al agregar automáticamente fotos históricas coincidentes. Photo Discovery ofrece a los usuarios un conjunto de fotografías de antepasados y familiares desconocidas, procedentes de árboles genealógicos que han sido aportados por otros. Los usuarios pueden añ
http://www.businesswire.com/news/home/20170216005439/es/?feedref=JjAwJuN...
20170216005439es


<br /> Mazor Robotics Reports Record Fourth Quarter and Full Year 2016 Results<br />Thu, 16 Feb 2017 09:30:00 UT
CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, reported record revenue for the fourth quarter and full year ended December 31, 2016. As previously announced, the Company received purchase orders for 21 systems in the fourth quarter and ended the year with a backlog of 21 systems, including 18 Mazor X systems, its transformative platform for spine surgeries, which was commercially launched in Oc
http://www.businesswire.com/news/home/20170216005300/en/Mazor-Robotics-R...
20170216005300en


<br /> Pixium Vision anuncia el primer implante y activación de IRIS® II en España<br />Thu, 16 Feb 2017 08:46:00 UT

PARÍS & BARCELONA, España--(BUSINESS WIRE)--Pixium Vision (Paris:PIX), una compañía que desarrolla sistemas de visión biónica innovadores con la intención de permitir a los pacientes que han perdido la vista conseguir una vida más independiente, anuncia el primer implante y activación de IRIS® II en España. Este implante es parte del estudio clínico multicéntrico que Pixium Vision está llevando a cabo para valorar el funcionamiento de IRIS® II, que se supone proporciona un tratamiento para comp
http://www.businesswire.com/news/home/20170216005465/es/?feedref=JjAwJuN...
20170216005465es


<br /> CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences ed ERS Genomics riportano un aggiornamento sulla disputa legale per interferenza relativa al brevetto statunitense sul CRISPR/Cas9 e sulle concessioni...<br />Thu, 16 Feb 2017 08:04:00 UT
BASILEA, Svizzera, CAMBRIDGE, Mass., BERKELEY, Calif., e DUBLINO--(BUSINESS WIRE)--CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences ed ERS Genomics riportano un aggiornamento sulla disputa legale per interferenza relativa al brevetto statunitense sul CRISPR/Cas9 e sulle concessioni dei relativi brevetti nel Regno Unito CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), Caribou Biosciences, Inc. ed ERS Genomics Limited hanno diffuso un aggiornamento sull
http://www.businesswire.com/news/home/20170216005458/it/?feedref=JjAwJuN...
20170216005458it


<br /> Asterand Bioscience und MolecularMD kündigen Partnerschaft an: zur beschleunigten Validierung gezielter therapeutischer Biomarker, Optimierung, Entwicklung und Kommerzialisierung<br />Thu, 16 Feb 2017 07:13:00 UT

PORTLAND, Oregon (USA) und CAMBRIDGE, Massachusetts (USA) und DETROIT, Michigan (USA)--(BUSINESS WIRE)--Asterand Bioscience, der weltweit führende Anbieter von qualitativ hochwertigem und gut charakterisiertem menschlichen Gewebe und auf menschlichem Gewebe basierenden Forschungslösungen für Wissenschaftler im Bereich der Arzneimittelentdeckung, hat heute das Eingehen einer Partnerschaft mit MolecularMD angekündigt. Dadurch soll die Fachkompetenz von MolecularMD als Anbieter von Molekulardiagno
http://www.businesswire.com/news/home/20170215006472/de/?feedref=JjAwJuN...
20170215006472de


<br /> Vedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University School of Medicine and Leiden University Medical Center Focused on Food Allergies and C. difficile and Graft versus Host Disease<br />Thu, 16 Feb 2017 07:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University School of Medicine and Leiden University Medical Center Focused on Food Allergies and C. difficile
http://www.businesswire.com/news/home/20170215006392/en/Vedanta-Bioscien...
20170215006392en


<br /> Solasia and Lee’s Pharma Announce License, Promotion and Supply Agreement (the “Agreement”) for episil®<br />Thu, 16 Feb 2017 06:00:00 UT

TOKYO & HONG KONG--(BUSINESS WIRE)--New partnership for Solasia
http://www.businesswire.com/news/home/20170215006401/en/Solasia-Lee%E2%8...
20170215006401en


<br /> Pixium Vision Announces First Implantation and Activation of IRIS® II in Spain<br />Thu, 16 Feb 2017 06:00:00 UT

PARIS & BARCELONA, Spain--(BUSINESS WIRE)--Regulatory News: Pixium Vision (Paris:PIX), a company developing innovative bionic vision systems with the intention to enable patients who have lost their sight to lead more independent lives, announces the first implantation and activation of IRIS® II in Spain. This implantation is part of Pixium Vision’s ongoing multi-centre clinical trial to assess the performance of IRIS® II which is supposed to provide a treatment to compensate for blindness. The
http://www.businesswire.com/news/home/20170215006436/en/Pixium-Vision-An...
20170215006436en


<br /> Pixium Vision annonce la première implantation et activation d'IRIS®II en Espagne<br />Thu, 16 Feb 2017 06:00:00 UT

PARIS & BARCELONE, Espagne--(BUSINESS WIRE)--Regulatory News: Pixium Vision (Paris:PIX), société qui développe et commercialise des systèmes de vision bionique innovants en vue de permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce la première implantation et activation d’IRIS®II en Espagne. Cette implantation entre dans le cadre de l’essai clinique multicentrique mené par Pixium Vision, qui est censé apporter un traitement pour compenser la cécité. L’implant épi-
http://www.businesswire.com/news/home/20170215006437/fr/?feedref=JjAwJuN...
20170215006437fr


<br /> La Commission européenne autorise Zoetis à commercialiser Stronghold® Plus<br />Thu, 16 Feb 2017 05:18:00 UT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) a annoncé aujourd’hui que la Commission européenne autorisait la mise sur le marché du médicament Stronghold® Plus (sélamectine/sarolaner), combinaison de parasiticides à application locale qui traite contre les tiques, les puces, la gale auriculaire, les poux et les nématodes gastrointestinaux tout en prévenant de la dirofilariose chez les chats. Les vétérinaires de l’Union Européenne disposent à présent d’une option de traitement qui t
http://www.businesswire.com/news/home/20170215006465/fr/?feedref=JjAwJuN...
20170215006465fr


<br /> Riassunto: Zoetis ottiene l'approvazione della Commissione Europea per Stronghold® Plus<br />Thu, 16 Feb 2017 05:18:00 UT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) ha annunciato in data odierna di avere ottenuto l'autorizzazione della Commissione Europea per Stronghold® Plus (selamectina/sarolaner), un parassiticida di associazione topico per il trattamento di zecche, pulci, acari dell'orecchio, pidocchi e nematodi gastrointestinali e la prevenzione della filariosi nei gatti. I veterinari in tutta l'Unione Europea hanno ora a disposizione un'opzione terapeutica che offre i benefici di sarolaner, fa
http://www.businesswire.com/news/home/20170215006466/it/?feedref=JjAwJuN...
20170215006466it


Teva Files 2016 Annual Report on Form 20-FWed, 15 Feb 2017 23:10:00 UT
JERUSALEM--(BUSINESS WIRE)--In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has filed its 2016 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which
http://www.businesswire.com/news/home/20170215006382/en/Teva-Files-2016-...
20170215006382en


<br /> Asterand Bioscience et MolecularMD annoncent un partenariat visant à accélérer la validation, l'optimisation, le développement et la commercialisation de biomarqueurs thérapeutiques ciblés<br />Wed, 15 Feb 2017 22:52:00 UT

PORTLAND, Oregon CAMBRIDGE, Massachusetts et DÉTROIT--(BUSINESS WIRE)--Asterand Bioscience, fournisseur leader de tissus humains bien caractérisés de haute qualité ainsi que de solutions de recherche à base de tissus humains en appui de la découverte et du développement de médicaments, a annoncé aujourd'hui avoir conclu avec MolecularMD un partenariat visant à combiner l'expertise de MolecularMD, en tant que fournisseur de produits et services de diagnostic moléculaire, avec les capacités de va
http://www.businesswire.com/news/home/20170215006371/fr/?feedref=JjAwJuN...
20170215006371fr


<br /> Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference<br />Wed, 15 Feb 2017 22:29:00 UT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BIIB--Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
http://www.businesswire.com/news/home/20170215006358/en/Biogen-Present-2...
20170215006358en


<br /> RTI Surgical® Makes an Inducement Grant to Camille Farhat, New Chief Executive Officer<br />Wed, 15 Feb 2017 21:55:00 UT

ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical Makes an Inducement Grant to Camille Farhat, Chief Executive Officer
http://www.businesswire.com/news/home/20170215006316/en/RTI-Surgical%C2%...
20170215006316en


<br /> Zoetis Receives European Commission Approval for Stronghold® Plus<br />Wed, 15 Feb 2017 21:30:00 UT

PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis has received European Commission approval for a new combination product for cats in the European Union.
http://www.businesswire.com/news/home/20170215006296/en/Zoetis-Receives-...
20170215006296en


<br /> Anika Reports Fourth Quarter and Full Year 2016 Financial Results<br />Wed, 15 Feb 2017 21:05:00 UT

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the fourth quarter and full year ended December 31, 2016, along with business progress in the periods. “Anika delivered another year of very strong growth, with 17% product revenue growth for the full year of 2016,” said Charles H. Sherwood, Ph.D.,
http://www.businesswire.com/news/home/20170215006178/en/Anika-Reports-Fo...
20170215006178en


<br /> BioTime, Inc. Announces Closing of Public Offering of Common Stock<br />Wed, 15 Feb 2017 21:05:00 UT
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,453,704, shares of its common stock in the offering, which includes 972,222 shares of its common stock issued in connection with the exercise in full of the underwriters’ over allotment option.
http://www.businesswire.com/news/home/20170215006232/en/BioTime-Announce...
20170215006232en


<br /> Insulet Completes Acquisition of U.S. Manufacturing Facility in Acton, Massachusetts<br />Wed, 15 Feb 2017 21:01:00 UT

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced the Company has completed the acquisition of a facility in Acton, Massachusetts to establish a U.S. manufacturing location in the United States. The state-of-the-art facility, when outfitted with highly-automated manufacturing equipment, will provide capacity for Insulet to manufacture on a sin
http://www.businesswire.com/news/home/20170215006221/en/Insulet-Complete...
20170215006221en


<br /> CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh<br />Wed, 15 Feb 2017 21:01:00 UT

ALAMEDA, Calif.--(BUSINESS WIRE)--Please replace the release dated February 6, 2017, with the following corrected version due to multiple revisions. The corrected release reads: BIOTIME EXPANDS OPHTHALMOLOGY PORTFOLIO WITH GLOBAL IN-LICENSING AGREEMENT FOR NEXT-GENERATION RETINAL DISEASE THERAPY FROM UNIVERSITY OF PITTSBURGH Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness BioTime, Inc. (NYSE MKT:BTX), a c
http://www.businesswire.com/news/home/20170206005380/en/CORRECTING-REPLA...
20170206005380en


<br /> CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.<br />Wed, 15 Feb 2017 19:49:00 UT
BASEL, Switzerland & CAMBRIDGE, Mass. & BERKELEY, Calif. & DUBLIN--(BUSINESS WIRE)--CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), Caribou Biosciences, Inc., and ERS Genomics Limited provide an update on the Patent Trial & Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office (“USPTO”) decision on the motions filed by the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively, “UC”), on one hand, and the Broad I
http://www.businesswire.com/news/home/20170215006197/en/CRISPR-Therapeut...
20170215006197en


<br /> Riassunto: Masimo annuncia di aver ottenuto l’autorizzazione all’uso del marchio CE per la misurazione del tasso di respirazione su MightySat™ Rx<br />Wed, 15 Feb 2017 19:39:00 UT

NEUCHÂTEL, Svizzera--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) ha annunciato oggi di aver ottenuto l’autorizzazione all’uso del marchio CE per la misurazione del tasso di respirazione tramite il pletismografo (RRpTM) del pulsossimetro da dito MightySat™ Rx. MightySat è un dispositivo non invasivo che misura e visualizza la saturazione di ossigeno del sangue funzionale (SpO2), la frequenza delle pulsazioni e l’indice di perfusione con l’opzione di aggiunta dell’indice di variabilità pletismografica
http://www.businesswire.com/news/home/20170215006184/it/?feedref=JjAwJuN...
20170215006184it


<br /> Riassunto: Asterand Bioscience e MolecularMD annunciano di aver instaurato un rapporto di collaborazione per accelerare la convalida, l’ottimizzazione, lo sviluppo e la commercializzazione di biomarcatori terapeutici mirati<br />Wed, 15 Feb 2017 18:29:00 UT

PORTLAND, Oregon, CAMBRIDGE, Massachusetts, e DETROIT--(BUSINESS WIRE)--Asterand Bioscience, una prestigiosa società impegnata nell’offerta di campioni di tessuto umano d’alta qualità e ben caratterizzati e di soluzioni per la ricerca basata su tessuto umano a sostegno della scoperta e dello sviluppo di farmaci, ha annunciato in data odierna di aver instaurato una collaborazione con MolecularMD per abbinare le competenze di MolecularMD quale fornitore di prodotti e servizi di diagnostica moleco
http://www.businesswire.com/news/home/20170215006098/it/?feedref=JjAwJuN...
20170215006098it


<br /> $38.70 Billion Regenerative Medicine Market by Therapy, Product & Applications - Forecast to 2021 - Research and Markets<br />Wed, 15 Feb 2017 18:24:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Regenerative Medicine Market - Forecast to 2021" report to their offering. The global Regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6% from 2016 to 2021. The major factor driving the growth of regenerative medicine market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic d
http://www.businesswire.com/news/home/20170215006089/en/38.70-Billion-Re...
20170215006089en


<br /> Microfluidics Market: By Material, Application, Diagnostic, Drug Delivery & Region - Forecast (2016-2022) - Research and Markets<br />Wed, 15 Feb 2017 17:59:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Microfluidics Market - Forecast (2016-2022)" report to their offering. Microfluidics, also referred to as lab-on-chip or micrototal analysis assisting in biological and chemical analysis, is a technology in the healthcare application that deals with the study of flow of liquids through microscopic channels. It is characterized by control and manipulation of fluids at sub-millimeter scale. Microfluidics involve desi
http://www.businesswire.com/news/home/20170215006053/en/Microfluidics-Ma...
20170215006053en


<br /> Resumen: LivaNova reconoce el día internacional de la epilepsia<br />Wed, 15 Feb 2017 17:33:00 UT

LONDRES--(BUSINESS WIRE)--Hoy es el Día internacional de la epilepsia, un evento mundial que se celebra anualmente el segundo lunes de febrero, con el fin de promover el conocimiento sobre la epilepsia en todo el mundo. El hilo conductor en este día es poner la epilepsia en primer plano y llamar la atención sobre la necesidad de mayor concienciación y comprensión, una legislación adecuada, un diagnóstico mejorado y servicios de tratamiento y un aumento de la investigación a fin de mejora las vi
http://www.businesswire.com/news/home/20170215005995/es/?feedref=JjAwJuN...
20170215005995es


<br /> NICEのガイダンスは患者の安定胸痛の原因判定に役立てるようHeartFlow FFRct Analysisを推奨<br />Wed, 15 Feb 2017 16:14:00 UT

米カリフォルニア州レッドウッドシティー--(BUSINESS WIRE)--(ビジネスワイヤ) -- 英国立医療技術評価機構(NICE)は本日、患者の安定胸痛の原因判定に役立てるよう、HeartFlow® FFRct Analysis使用のガイダンスを発出しました。ハートフローが開発したHeartFlow FFRct Analysisは非侵襲的技術として初めて、冠動脈疾患の範囲と、疾患が心臓への血流に及ぼす影響の両方に関しての詳細な知見を与え、医師が適切な治療法を選択できるようにするものです。 NICEは、HeartFlow FFRct Analysisを最近発症した安定胸痛の患者で使用するよう推奨しています。NICEは証拠に基づき、本技術が安全で、診断精度が高く、侵襲的冠動脈造影の必要性を排除できる可能性があると結論付けました。NICEはさらに、他の検査法すべてと比較した場合、HeartFlow FFRct Analysisを使用することで、英国の国民保健サービスが、不必要な侵襲的検査と治療の回避を通じて患者1人当たり約214ポンドを節約できる見込みがあると結論付けました。 本日発
http://www.businesswire.com/news/home/20170215005843/ja/?feedref=JjAwJuN...
20170215005843ja


<br /> IntegenX anuncia RapidHIT®, un nuevo kit de cartucho que optimiza la manejabilidad del sistema de identificación rápido de ADN con mejor rendimiento<br />Wed, 15 Feb 2017 16:08:00 UT
PLEASANTON, California--(BUSINESS WIRE)--IntegenX Inc., líder del mercado en tecnología de identificación rápida de ADN humano, ha anunciado el lanzamiento del cartucho RapidHIT EXT para muestras extraídas y cuantificadas. Dotado de un flujo de identificación del ADN muy rápido y práctico sin precedentes, el kit permite el análisis de muestras de pruebas en un laboratorio de medicina legal. Mediante la utilización del ADN purificado que se ha extraído y cuantificado con protocolos de laboratori
http://www.businesswire.com/news/home/20170215005834/es/?feedref=JjAwJuN...
20170215005834es


<br /> Tricida Announces Hiring of Wilhelm Stahl as Chief Technology Officer and Senior Vice President<br />Wed, 15 Feb 2017 15:38:00 UT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc., hires Dr. Wilhelm Stahl, Ph.D., as Chief Technology Officer; Dr. Stahl's experience will be a key asset as Tricida moves into late stage development of lead candidate TRC101.
http://www.businesswire.com/news/home/20170215005786/en/Tricida-Announce...
20170215005786en


<br /> Amgen’s Repatha CVOT Results Are Potential Game-Changer for Lipid-Lowering Treatment<br />Wed, 15 Feb 2017 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--$AMGN #BPINews--In its latest Cardiology Report, BioPharm Insight (BPI) reported that Amgen’s Repatha Phase III FOURIER trial will be deemed successful by experts if it shows a 35% reduction in major cardiovascular events (MACE). Get the Report: http://www.biopharminsight.com/cardiology-report-january-2017 The report from BPI, the most comprehensive life science news and analytical solution, highlights recent editorial coverage of cardiology therapies in development that have potenti
http://www.businesswire.com/news/home/20170215005317/en/Amgen%E2%80%99s-...
20170215005317en


<br /> Global Next-Generation Sequencing Market (Forecast: 2016–2021) – Top-Down Analytics<br />Wed, 15 Feb 2017 15:00:00 UT

LOS ANGELES--(BUSINESS WIRE)--#NGS--Top-Down Analytics, a Los Angeles-based market research and management consulting firm has announced its new report entitled “The Global Next Generation Sequencing, Forecast 2016–2021.”
http://www.businesswire.com/news/home/20170215005321/en/Global-Next-Gene...
20170215005321en


<br /> Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization<br />Wed, 15 Feb 2017 15:00:00 UT

PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT--(BUSINESS WIRE)--#drugdiscovery--Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership with MolecularMD to combine MolecularMD’s expertise as a provider of molecular diagnostics products and services with Asterand Bio’s drug target and candidate validation capabilities. MolecularMD is a molecular diagnostics company that devel
http://www.businesswire.com/news/home/20170215005195/en/Asterand-Bioscie...
20170215005195en